STOCK TITAN
  1. Home
  2. SRNEQ

Sorrento Therapeutics (SRNEQ) Stock Price, News & Analysis

SRNEQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
155 252 sessions, June 9, 2023 to June 10, 2024
Largest daily move
+6400% close of May 20, 2024
1-year change
-96.8% closing prices, June 9, 2023 to June 10, 2024
1-month change
-14.8% closing prices, May 10, 2024 to June 10, 2024

Company Description

SRNEQ declined 96.8% in the 12 months to June 10, 2024. The last closing price was $0.0115.

This page collects what Stock Titan holds for SRNEQ, including price data and latest news.

Stock Performance

Chart
$0.0115
No recent trading
Last close: June 10, 2024
-96.8%
1 year to June 10, 2024
-
Market Cap
-
Shares outstanding

Sorrento Therapeutics (SRNEQ) closed at $0.0115 on June 10, 2024. In the 12 months to June 10, 2024, the price lost 96.8%.

See what a $1,000 investment in SRNEQ would be worth today

Average down calculator for SRNEQ

SRNEQ Metrics & Rankings

June 2024
+1.8%
—
2024
-90.7%
—

Price returns through June 10, 2024. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

View All
-2.54%

Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company

+3.57%

Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19

clinical trial covid-19
+36.74%

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

clinical trial
-10.35%

Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid

+6.67%

Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders

dividends
+4.82%

Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study

clinical trial
+0.72%

Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19

clinical trial covid-19
-3.32%

Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness

+18.23%

Sorrento Therapeutics, Inc.'s Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers' Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Brokerage Firms to Deliver the Stock to Individual Accounts

dividends
+8.92%

Sorrento Therapeutics, Inc.'s Bankruptcy Court Extends the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend

dividends

Sorrento Therapeutics has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 3 with negative movement. Key topics include clinical trial, covid-19, dividends. View all SRNEQ news →

SEC Filings

No SEC filings available for SRNEQ.

Frequently Asked Questions

Sorrento Therapeutics (SRNEQ) has no recent trading. Its last close was $0.0115 on June 10, 2024.